首页 > 最新文献

NUCLEAR MEDICINE REVIEW最新文献

英文 中文
Vertebral photopenia on [67Ga]Ga-citrate and [18F]FDG PET/CT imaging in a patient with non-Hodgkin lymphoma. [67Ga]枸橼酸镓和[18F]FDG PET/CT成像显示非霍奇金淋巴瘤患者椎体光减少。
IF 0.9 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2023-01-01 DOI: 10.5603/NMR.a2022.0042
Georgios Meristoudis, Ioannis Ilias, Vasilios Giannakopoulos

A cold vertebral defect is an uncommon finding, especially in Gallium-67-citrate ([67Ga]Ga-citrate) - and [18F]fluorodeoxyglucose ([18F]FDG) - avid lymphomas, representing a diagnostic challenge. Here, we present the case of a patient with non-Hodgkin lymphoma (NHL), in whom the [67Ga]Ga-citrate and [18F]FDG scans showed a diffuse skeletal uptake pattern with concomitant appearance of a cold vertebral defect. Awareness of the different causes of such uptake patterns and accurate clinical information is important to avoid misinterpretation of nuclear studies in oncologic patients.

冷椎体缺损是一种罕见的发现,特别是在67-柠檬酸镓([67Ga] ga -柠檬酸镓)和[18F]氟脱氧葡萄糖([18F]FDG)淋巴瘤中,这是一种诊断挑战。在此,我们报告了一例非霍奇金淋巴瘤(NHL)患者,其[67Ga]枸橼酸镓和[18F]FDG扫描显示弥漫性骨骼摄取模式,并伴有椎体冷缺陷。了解这种摄取模式的不同原因和准确的临床信息对于避免对肿瘤患者核研究的误解很重要。
{"title":"Vertebral photopenia on [67Ga]Ga-citrate and [18F]FDG PET/CT imaging in a patient with non-Hodgkin lymphoma.","authors":"Georgios Meristoudis,&nbsp;Ioannis Ilias,&nbsp;Vasilios Giannakopoulos","doi":"10.5603/NMR.a2022.0042","DOIUrl":"https://doi.org/10.5603/NMR.a2022.0042","url":null,"abstract":"<p><p>A cold vertebral defect is an uncommon finding, especially in Gallium-67-citrate ([67Ga]Ga-citrate) - and [18F]fluorodeoxyglucose ([18F]FDG) - avid lymphomas, representing a diagnostic challenge. Here, we present the case of a patient with non-Hodgkin lymphoma (NHL), in whom the [67Ga]Ga-citrate and [18F]FDG scans showed a diffuse skeletal uptake pattern with concomitant appearance of a cold vertebral defect. Awareness of the different causes of such uptake patterns and accurate clinical information is important to avoid misinterpretation of nuclear studies in oncologic patients.</p>","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":"26 0","pages":"38-39"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10801902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An approach to develop personalized radiopharmaceuticals by modifying 2-[18F]fluoro-2-deoxy-D-glucose (2-[18F]FDG). 通过修饰2-[18F]氟-2-脱氧-D-葡萄糖(2-[18F]FDG)开发个性化放射性药物的方法。
IF 0.9 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2023-01-01 DOI: 10.5603/nmr.93869
Gergana Simeonova, Boyan Todorov

Background: A challenge for modern medicine is the development of clinical protocols for precise diagnosis and therapy. This study aimed to propose a simple method for modification of 2-[18F]FDG used routinely in hospitals in a way, appropriate for patients' personalized radiopharmaceuticals approach.

Material and methods: For the purposes of the presented study chemo selective method for indirect radiofluorination was applauded to custom synthesized aminooxy- and hydrazine-functionalized tetrazines for 18F-glycolation via oxime or hydrazone formation. 2-[18F]FDG produced with medical baby cyclotron in Nuclear Medicine Clinic at the University Hospital St. Marina-Varna, was used. Thin layer chromatography (TLC) and radio TLC were used to follow the progress of synthesis and to determine radio chemical yield (RCY).

Results: The 2-[18F]FDG was modified with two bifunctional tetrazines aminooxy-acetic acid-6-(2-aminooxy-acetoxy)-[1,2,4,5] tetrazin-3-yl ester (Tz1) and {3-[4-(6-phenyl-[1,2,4,5]tetrazin-3-yl)-phenoxy]-propyl}-hydrazine (Tz2) via oxime and hydrazone formation. The radiolabeling was carried out as one-pot reaction with following parameters: temperature 70-75°C; catalyst p- diaminobenzene (Cat.); pH = 4.2; time 30 minutes; RCY = 70-99%. The radiolabeled tetrazines are appropriate for further bioorthogonal (pretargeting) strategy by click reactions with trans-cyclooctene conjugated bioactive molecules. The methodology is applicable to standard clinical conditions.

背景:现代医学面临的挑战是开发精确诊断和治疗的临床方案。本研究旨在提出一种简单的方法来修改医院常规使用的2-[18F]FDG,使其适合患者的个性化放射药物方法。材料和方法:为了本研究的目的,化学选择性间接放射性氟化方法被认为是定制合成的氨基氧基和肼官能化四嗪,用于通过肟或腙形成18F的糖酵解。使用圣玛丽娜·瓦尔纳大学医院核医学诊所的医用婴儿回旋加速器生产的2-[18F]FDG。采用薄层色谱(TLC)和放射线薄层色谱法对2-[18F]FDG的合成过程进行跟踪,并测定其放化产率。放射性标记作为一锅反应进行,参数如下:温度70-75°C;催化剂对-二氨基苯(Cat);pH=4.2;时间30分钟;RCY=70-99%。放射性标记的四嗪适合通过与反式环辛烯缀合的生物活性分子的点击反应进行进一步的生物正交(预靶向)策略。该方法适用于标准临床条件。
{"title":"An approach to develop personalized radiopharmaceuticals by modifying 2-[18F]fluoro-2-deoxy-D-glucose (2-[18F]FDG).","authors":"Gergana Simeonova,&nbsp;Boyan Todorov","doi":"10.5603/nmr.93869","DOIUrl":"https://doi.org/10.5603/nmr.93869","url":null,"abstract":"<p><strong>Background: </strong>A challenge for modern medicine is the development of clinical protocols for precise diagnosis and therapy. This study aimed to propose a simple method for modification of 2-[18F]FDG used routinely in hospitals in a way, appropriate for patients' personalized radiopharmaceuticals approach.</p><p><strong>Material and methods: </strong>For the purposes of the presented study chemo selective method for indirect radiofluorination was applauded to custom synthesized aminooxy- and hydrazine-functionalized tetrazines for 18F-glycolation via oxime or hydrazone formation. 2-[18F]FDG produced with medical baby cyclotron in Nuclear Medicine Clinic at the University Hospital St. Marina-Varna, was used. Thin layer chromatography (TLC) and radio TLC were used to follow the progress of synthesis and to determine radio chemical yield (RCY).</p><p><strong>Results: </strong>The 2-[18F]FDG was modified with two bifunctional tetrazines aminooxy-acetic acid-6-(2-aminooxy-acetoxy)-[1,2,4,5] tetrazin-3-yl ester (Tz1) and {3-[4-(6-phenyl-[1,2,4,5]tetrazin-3-yl)-phenoxy]-propyl}-hydrazine (Tz2) via oxime and hydrazone formation. The radiolabeling was carried out as one-pot reaction with following parameters: temperature 70-75°C; catalyst p- diaminobenzene (Cat.); pH = 4.2; time 30 minutes; RCY = 70-99%. The radiolabeled tetrazines are appropriate for further bioorthogonal (pretargeting) strategy by click reactions with trans-cyclooctene conjugated bioactive molecules. The methodology is applicable to standard clinical conditions.</p>","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":"26 0","pages":"109-115"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41165366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
123I-ioflupane SPECT in the assessment of Parkinson’s disease in a patient with retinitis pigmentosa 123I-ioflupane SPECT评估一例视网膜色素变性患者的帕金森病
IF 0.9 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2022-10-27 DOI: 10.5603/nmr.a2022.0040
Francesco Dondi, M. Gregorelli, D. Albano, F. Bertagna, R. Giubbini
{"title":"123I-ioflupane SPECT in the assessment of Parkinson’s disease in a patient with retinitis pigmentosa","authors":"Francesco Dondi, M. Gregorelli, D. Albano, F. Bertagna, R. Giubbini","doi":"10.5603/nmr.a2022.0040","DOIUrl":"https://doi.org/10.5603/nmr.a2022.0040","url":null,"abstract":"","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":"1 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2022-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42306672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial Note. 编辑说明。
IF 0.6 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2022-01-01 DOI: 10.5603/NMR.2022.0001
Grzegorz Kamiński
{"title":"Editorial Note.","authors":"Grzegorz Kamiński","doi":"10.5603/NMR.2022.0001","DOIUrl":"10.5603/NMR.2022.0001","url":null,"abstract":"","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":"25 1","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39902627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
99mTc-Vitamin C SPECT/CT imaging in SARS-CoV-2 associated pneumonia. 99mtc -维生素C在SARS-CoV-2相关性肺炎中的SPECT/CT成像
IF 0.9 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2022-01-01 DOI: 10.5603/NMR.a2022.0026
Haluk B Sayman, Kubra N Toplutas, James Tunick, Omer Aras

We present the first 99mTc-Vitamin C single-photon emission computed tomography/computed tomography (SPECT/CT) images obtained in patients with SARS-CoV-2 (COVID-19) infection. The CT portion of SPECT/CT images showed mostly peripheral patchy and ground-glass opacities in both lungs, which are consistent with a diagnosis of SARS-CoV-2-associated pneumonia in both patients. 99mTc-Vitamin C SPECT images showed increased tracer uptake corresponding to abnormal lung findings seen on CT in patient 1 who was newly diagnosed and treatment naïve. However, no abnormal uptake corresponding to lung CT findings was seen in patient 2 who received anti-SARS-CoV-2 treatment.

我们提出了在SARS-CoV-2 (COVID-19)感染患者中获得的第一批99mtc -维生素C单光子发射计算机断层扫描/计算机断层扫描(SPECT/CT)图像。SPECT/CT图像的CT部分显示双肺主要为外周斑片状和磨玻璃样混浊,这与两例患者的sars - cov -2相关肺炎的诊断一致。99mtc -维生素C SPECT图像显示示踪剂摄取增加,与新诊断和治疗的患者1的CT异常肺部表现相对应naïve。然而,在接受抗sars - cov -2治疗的患者2中,未见肺部CT检查结果对应的异常摄取。
{"title":"99mTc-Vitamin C SPECT/CT imaging in SARS-CoV-2 associated pneumonia.","authors":"Haluk B Sayman,&nbsp;Kubra N Toplutas,&nbsp;James Tunick,&nbsp;Omer Aras","doi":"10.5603/NMR.a2022.0026","DOIUrl":"https://doi.org/10.5603/NMR.a2022.0026","url":null,"abstract":"<p><p>We present the first 99mTc-Vitamin C single-photon emission computed tomography/computed tomography (SPECT/CT) images obtained in patients with SARS-CoV-2 (COVID-19) infection. The CT portion of SPECT/CT images showed mostly peripheral patchy and ground-glass opacities in both lungs, which are consistent with a diagnosis of SARS-CoV-2-associated pneumonia in both patients. 99mTc-Vitamin C SPECT images showed increased tracer uptake corresponding to abnormal lung findings seen on CT in patient 1 who was newly diagnosed and treatment naïve. However, no abnormal uptake corresponding to lung CT findings was seen in patient 2 who received anti-SARS-CoV-2 treatment.</p>","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":"25 2","pages":"127-128"},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878461/pdf/nihms-1864454.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9626094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Degree of agreement between dacryoscintigraphy and dacryocystography examinations results in primary acquired nasolacrimal duct obstruction. 原发性获得性鼻泪管阻塞的泪道造影与泪道造影检查结果的一致程度。
IF 0.9 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2022-01-01 DOI: 10.5603/NMR.a2022.0004
Elyas Aditya, Yunia Irawati, Benny Zulkarnaien, Joedo Prihartono

Background: This diagnostic study aimed to assess degree of agreement between dacryoscintigraphy and dacryocystography as supporting examinations in patients with primary acquired nasolacrimal duct obstruction (PANDO). Patients with PANDO who complained of epiphora and visited our outpatient clinic were subsequently sent for dacryoscintigraphy and dacryocystography examinations. Side effects and convenience of both examinations were assessed by observation and questionnaire.

Material and methods: Through irrigation and probing, there were 47 out of 62 eyes were found with PANDO. As much as 87.1% subjects were female, with mostly (74.2%) aged > 40 years old. With dacryoscintigraphy, time needed to reach sac was 0 minutes, 5 minutes (duct), and 12.5 minutes (nasal cavity).

Results: Degree of agreement between both examinations was 83.8% to determine obstruction and 70.9% to locate obstruction. There were 22 subjects complained about pain in dacryocystography examination while none with dacryoscintigraphy (p < 0.005). Sixteen subjects feel dacryoscintigraphy examination was more convenient, eleven subjects feel dacryocystohraphy was more convenient, while 4 subjects feel the two examinations were similar.

Conclusions: Even though dacryocystography examination was considered more painful than dacryoscintigraphy, both examinations had high convenience level for patients. Dacryoscintigraphy and dacryocystography also had a good agreement in detecting and locating obstruction in PANDO.

背景:本诊断研究旨在评估泪道造影术和泪道造影术作为原发性获得性鼻泪管阻塞(PANDO)患者辅助检查的一致性程度。患有PANDO的患者在就诊后,被送去做泪囊造影和泪囊造影检查。采用观察法和问卷法评价两种检查方法的副作用和便利性。材料与方法:62只眼经冲洗、探查,发现有47只眼存在PANDO。87.1%的受试者为女性,其中年龄> 40岁的占74.2%。泪珠造影显示,到达囊所需时间为0分钟,5分钟(导管),12.5分钟(鼻腔)。结果:两种检查诊断梗阻的符合度为83.8%,定位梗阻的符合度为70.9%。22名患者在泪囊造影检查中有痛感,而泪囊造影检查中无痛感(p < 0.005)。16名受试者认为泪囊造影术检查更方便,11名受试者认为泪囊造影术检查更方便,4名受试者认为两者检查相似。结论:尽管泪囊造影检查被认为比泪囊造影更痛苦,但两种检查对患者的方便程度都很高。泪囊造影和泪囊造影对PANDO阻塞的发现和定位也有很好的一致性。
{"title":"Degree of agreement between dacryoscintigraphy and dacryocystography examinations results in primary acquired nasolacrimal duct obstruction.","authors":"Elyas Aditya,&nbsp;Yunia Irawati,&nbsp;Benny Zulkarnaien,&nbsp;Joedo Prihartono","doi":"10.5603/NMR.a2022.0004","DOIUrl":"https://doi.org/10.5603/NMR.a2022.0004","url":null,"abstract":"<p><strong>Background: </strong>This diagnostic study aimed to assess degree of agreement between dacryoscintigraphy and dacryocystography as supporting examinations in patients with primary acquired nasolacrimal duct obstruction (PANDO). Patients with PANDO who complained of epiphora and visited our outpatient clinic were subsequently sent for dacryoscintigraphy and dacryocystography examinations. Side effects and convenience of both examinations were assessed by observation and questionnaire.</p><p><strong>Material and methods: </strong>Through irrigation and probing, there were 47 out of 62 eyes were found with PANDO. As much as 87.1% subjects were female, with mostly (74.2%) aged > 40 years old. With dacryoscintigraphy, time needed to reach sac was 0 minutes, 5 minutes (duct), and 12.5 minutes (nasal cavity).</p><p><strong>Results: </strong>Degree of agreement between both examinations was 83.8% to determine obstruction and 70.9% to locate obstruction. There were 22 subjects complained about pain in dacryocystography examination while none with dacryoscintigraphy (p < 0.005). Sixteen subjects feel dacryoscintigraphy examination was more convenient, eleven subjects feel dacryocystohraphy was more convenient, while 4 subjects feel the two examinations were similar.</p><p><strong>Conclusions: </strong>Even though dacryocystography examination was considered more painful than dacryoscintigraphy, both examinations had high convenience level for patients. Dacryoscintigraphy and dacryocystography also had a good agreement in detecting and locating obstruction in PANDO.</p>","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":"25 1","pages":"12-17"},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10535483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiopharmaceutical for detecting PSMA - positive metastatic colon cancer: Matched-pair comparison of 18F-BF3-Cy3-ACUPA and 68Ga-PSMA PET/MRI. 放射性药物检测PSMA阳性转移性结肠癌:18f - bf3 - cy3 - acua与68Ga-PSMA PET/MRI的配对比较
IF 0.9 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2022-01-01 DOI: 10.5603/NMR.a2022.0027
Omer Aras, Cetin Demirdag, Harikrishna Kommidi, Richard Ting, Haluk B Sayman

Prostate-specific membrane antigen (PSMA) - based radiopharmaceuticals are promising for the evaluation of PSMA-positive non-prostate cancers. In this case study, 18F-BF3-Cy3-ACUPA and 68Ga-PSMA positron emission tomography/magnetic resonance imaging (PET/MRI) were compared in a patient with metastatic colon cancer. Both 18F-BF3-Cy3-ACUPA and 68Ga-PSMA PET/MRI showed biopsy-proven metastatic left external iliac adenopathy, highlighting the feasibility of PSMA uptake in PET/MRI of metastatic nodal disease from colon cancer. Along with imaging evaluation, PSMA-based radiopharmaceuticals may also be used as a surrogate imaging tracer for potential theranostic applications using alpha or beta emitters in the context of PSMA-directed radiopharmaceutical therapy in advanced and progressive colorectal cancer.

基于前列腺特异性膜抗原(PSMA)的放射性药物在PSMA阳性非前列腺癌的评估中具有广阔的应用前景。在本病例研究中,我们比较了一例转移性结肠癌患者的18f - bf3 - cy3 - acua和68Ga-PSMA正电子发射断层扫描/磁共振成像(PET/MRI)。18f - bf3 - cy3 -针灸和68Ga-PSMA PET/MRI均显示活检证实的转移性左髂外腺病,强调PSMA摄取在结肠癌转移性淋巴结病的PET/MRI中的可行性。随着成像评估,基于psma的放射性药物也可以用作替代成像示踪剂,用于在psma导向的晚期和进展性结直肠癌放射药物治疗中使用α或β发射器的潜在治疗应用。
{"title":"Radiopharmaceutical for detecting PSMA - positive metastatic colon cancer: Matched-pair comparison of 18F-BF3-Cy3-ACUPA and 68Ga-PSMA PET/MRI.","authors":"Omer Aras,&nbsp;Cetin Demirdag,&nbsp;Harikrishna Kommidi,&nbsp;Richard Ting,&nbsp;Haluk B Sayman","doi":"10.5603/NMR.a2022.0027","DOIUrl":"https://doi.org/10.5603/NMR.a2022.0027","url":null,"abstract":"<p><p>Prostate-specific membrane antigen (PSMA) - based radiopharmaceuticals are promising for the evaluation of PSMA-positive non-prostate cancers. In this case study, 18F-BF3-Cy3-ACUPA and 68Ga-PSMA positron emission tomography/magnetic resonance imaging (PET/MRI) were compared in a patient with metastatic colon cancer. Both 18F-BF3-Cy3-ACUPA and 68Ga-PSMA PET/MRI showed biopsy-proven metastatic left external iliac adenopathy, highlighting the feasibility of PSMA uptake in PET/MRI of metastatic nodal disease from colon cancer. Along with imaging evaluation, PSMA-based radiopharmaceuticals may also be used as a surrogate imaging tracer for potential theranostic applications using alpha or beta emitters in the context of PSMA-directed radiopharmaceutical therapy in advanced and progressive colorectal cancer.</p>","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":"25 2","pages":"129-130"},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878462/pdf/nihms-1863381.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9626090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
SPECT-CT Imaging with [99mTc]PSMA-T4 in patients with Recurrent Prostate Cancer. [99mTc]PSMA-T4在复发性前列腺癌患者中的SPECT-CT成像
IF 0.9 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2021-01-01 DOI: 10.5603/NMR.2021.0018
Sonya Sergieva, Radoslav Mangaldgiev, Milena Dimcheva, Kamen Nedev, Zahary Zahariev, Bozhil Robev
<p><strong>Background: </strong>Prostate-specific membrane antigen (PSMA) is a cell surface glycoprotein with a large extracellular domain with overexpression of the prostatic tumour cells. Several small molecules of PSMA ligands of inhibitors binding to the active site of PSMA were developed. [99mTc]Tc-PSMA-T4 is a new radiopharmaceutical (Polatom) for imaging loco-regional metastases and/or local relapse in patients with prostate cancer. The purpose of this work was to evaluate the clinical application of SPECT-CT imaging with [99mTc]Tc-PSMA-T4 in patients with recurrent prostate cancer.</p><p><strong>Material and methods: </strong>Thirty-six patients with prostate cancer, aged 60-80 years with biochemical relapse of PSA (ranged from 0.1 to 73 ng/mL) were included. Three patients were studied after tru-cut biopsy, hormonal and cytoreductive radiotherapy and 33 patients out of 36 - after radical treatment (total prostatectomy or definitive radiotherapy of the tumour). All of them underwent whole-body imaging examinations with subsequent target SPECT-CT studies of the pelvis, abdomen and/or chest, 1-3 hrs post i.v. administration of [99mTc]Tc-PSMA-T4. The average activity dose was 6.3 MBq/kg in a man of 70 kg. A Dual-head SPECT-CT gamma camera with a low dose CT scan (Symbia T2, Siemens) was used. The images were interpreted based on all other clinical and radiological data. Follow-up could be conducted in 11/36 patients during that period.</p><p><strong>Results: </strong>Normal biodistribution of the radiopharmaceutical with high activity background was observed in the liver, spleen, kidneys, lacrimal and salivary glands, bowels and urinary bladder. Positive imaging for local relapse in the prostate bad was imaged in 21 patients, lymph node metastases - in 16 cases, bone lesions - in 10 cases, pulmonary metastases - in 2 cases, hepatic lesions were visualised in one of them and in another - adrenal suprarenal metastasis with intensive tracer uptake significant for overexpression of PSMA. There was a suspicion for local recurrences in 4 patients with negative MRT studies who were followed up. In 3 cases, previously treated bone metastases were partially negative without tracer uptake, only some progressive bone lesions were positive. Five patients were with negative results. Sensitivity was 84.37% (27/32), specificity - 100% (4/4) and accuracy - 86.11% (31/36).</p><p><strong>Conclusions: </strong>In conclusion SPECT-CT imaging with [99mTc]Tc-PSMA-T4 could be applied in patients with prostate cancer for the diagnosis of recurrent disease to determine personalized treatment for each patient. Specific uptake of this tracer, depicted by SPECT-CT images has clinical importance of identifying and assessing PSMA expression before consideration of Radio Ligand Therapy (RLT) with [¹⁷⁷Lu]Lu-PSMA. SPECT-CT imaging with [99mTc]PSMA is promising and reliable nuclear medicine approach to monitoring therapeutic effect after treatment and for restaging of the di
背景:前列腺特异性膜抗原(PSMA)是一种细胞表面糖蛋白,具有较大的胞外结构域,在前列腺肿瘤细胞中过表达。开发了几种结合PSMA活性位点的PSMA抑制剂配体小分子。[99mTc]Tc-PSMA-T4是一种用于前列腺癌局部转移和/或局部复发的新型放射性药物(Polatom)。本研究的目的是评价[99mTc]Tc-PSMA-T4 SPECT-CT成像在复发性前列腺癌患者中的临床应用。材料与方法:36例前列腺癌患者,年龄60 ~ 80岁,PSA生化复发(0.1 ~ 73 ng/mL)。3例患者接受了真切活检、激素和细胞减少放疗,36例患者中有33例接受了根治性治疗(全前列腺切除术或肿瘤的最终放疗)。所有患者均在静脉注射[99mTc]Tc-PSMA-T4后1-3小时进行全身影像学检查,并对骨盆、腹部和/或胸部进行SPECT-CT靶检查。70公斤男性的平均活动剂量为6.3 MBq/kg。使用双头SPECT-CT伽马相机和低剂量CT扫描(Symbia T2, Siemens)。根据所有其他临床和放射学数据对图像进行解释。在此期间,有11/36的患者可以进行随访。结果:具有高活性背景的放射性药物在肝脏、脾脏、肾脏、泪腺、唾液腺、肠道和膀胱中生物分布正常。21例前列腺局部复发的阳性显像,16例淋巴结转移,10例骨病变,2例肺转移,1例肝病变可见,另1例肾上腺肾上转移伴强示踪剂摄取,PSMA过表达显著。在随访的4例MRT阴性患者中,怀疑局部复发。3例既往治疗的骨转移灶部分呈阴性,无示踪剂摄取,只有部分进展性骨病变呈阳性。阴性5例。灵敏度为84.37%(27/32),特异性为100%(4/4),准确度为86.11%(31/36)。结论:结论SPECT-CT扫描[99mTc]Tc-PSMA-T4可用于前列腺癌复发患者的诊断,为每位患者确定个性化的治疗方案。在考虑使用[¹⁷Lu]Lu-PSMA进行放射配体治疗(RLT)之前,通过SPECT-CT图像描述该示踪剂的特异性摄取对于识别和评估PSMA表达具有临床重要性。SPECT-CT成像[99mTc]PSMA是一种有前景的可靠的核医学方法,用于监测治疗后的治疗效果和疾病的再定位。
{"title":"SPECT-CT Imaging with [99mTc]PSMA-T4 in patients with Recurrent Prostate Cancer.","authors":"Sonya Sergieva,&nbsp;Radoslav Mangaldgiev,&nbsp;Milena Dimcheva,&nbsp;Kamen Nedev,&nbsp;Zahary Zahariev,&nbsp;Bozhil Robev","doi":"10.5603/NMR.2021.0018","DOIUrl":"https://doi.org/10.5603/NMR.2021.0018","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Prostate-specific membrane antigen (PSMA) is a cell surface glycoprotein with a large extracellular domain with overexpression of the prostatic tumour cells. Several small molecules of PSMA ligands of inhibitors binding to the active site of PSMA were developed. [99mTc]Tc-PSMA-T4 is a new radiopharmaceutical (Polatom) for imaging loco-regional metastases and/or local relapse in patients with prostate cancer. The purpose of this work was to evaluate the clinical application of SPECT-CT imaging with [99mTc]Tc-PSMA-T4 in patients with recurrent prostate cancer.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Material and methods: &lt;/strong&gt;Thirty-six patients with prostate cancer, aged 60-80 years with biochemical relapse of PSA (ranged from 0.1 to 73 ng/mL) were included. Three patients were studied after tru-cut biopsy, hormonal and cytoreductive radiotherapy and 33 patients out of 36 - after radical treatment (total prostatectomy or definitive radiotherapy of the tumour). All of them underwent whole-body imaging examinations with subsequent target SPECT-CT studies of the pelvis, abdomen and/or chest, 1-3 hrs post i.v. administration of [99mTc]Tc-PSMA-T4. The average activity dose was 6.3 MBq/kg in a man of 70 kg. A Dual-head SPECT-CT gamma camera with a low dose CT scan (Symbia T2, Siemens) was used. The images were interpreted based on all other clinical and radiological data. Follow-up could be conducted in 11/36 patients during that period.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Normal biodistribution of the radiopharmaceutical with high activity background was observed in the liver, spleen, kidneys, lacrimal and salivary glands, bowels and urinary bladder. Positive imaging for local relapse in the prostate bad was imaged in 21 patients, lymph node metastases - in 16 cases, bone lesions - in 10 cases, pulmonary metastases - in 2 cases, hepatic lesions were visualised in one of them and in another - adrenal suprarenal metastasis with intensive tracer uptake significant for overexpression of PSMA. There was a suspicion for local recurrences in 4 patients with negative MRT studies who were followed up. In 3 cases, previously treated bone metastases were partially negative without tracer uptake, only some progressive bone lesions were positive. Five patients were with negative results. Sensitivity was 84.37% (27/32), specificity - 100% (4/4) and accuracy - 86.11% (31/36).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;In conclusion SPECT-CT imaging with [99mTc]Tc-PSMA-T4 could be applied in patients with prostate cancer for the diagnosis of recurrent disease to determine personalized treatment for each patient. Specific uptake of this tracer, depicted by SPECT-CT images has clinical importance of identifying and assessing PSMA expression before consideration of Radio Ligand Therapy (RLT) with [¹⁷⁷Lu]Lu-PSMA. SPECT-CT imaging with [99mTc]PSMA is promising and reliable nuclear medicine approach to monitoring therapeutic effect after treatment and for restaging of the di","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":"24 2","pages":"70-81"},"PeriodicalIF":0.9,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39303509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
False-positive radioiodine uptake in breasts in a female haemodialysis patient. 女性血液透析患者乳房放射性碘摄取假阳性。
IF 0.9 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2021-01-01 DOI: 10.5603/NMR.2021.0030
Aleksandra Ledwon, Przemysław Soczomski, Ewa Paliczka-Cieslik, Aleksandra Blewąska, Daria Handkiewicz-Junak
The Na+/Isymporter (NIS) is an intrinsic plasma membrane glycoprotein that mediates the active uptake of Iin the thyroid and other tissues such as salivary glands, gastric mucosa and lactating mammary gland. Physiologically, NIS is expressed in the breast exclusively during gestation and lactation. In vitro and in vivo studies confirmed that lactogenic hormones, including prolactin, can induce functional NIS expression in mammary tissue. Hyperprolactinemia is common in patients with end-stage renal disease (ESRD).
{"title":"False-positive radioiodine uptake in breasts in a female haemodialysis patient.","authors":"Aleksandra Ledwon,&nbsp;Przemysław Soczomski,&nbsp;Ewa Paliczka-Cieslik,&nbsp;Aleksandra Blewąska,&nbsp;Daria Handkiewicz-Junak","doi":"10.5603/NMR.2021.0030","DOIUrl":"https://doi.org/10.5603/NMR.2021.0030","url":null,"abstract":"The Na+/Isymporter (NIS) is an intrinsic plasma membrane glycoprotein that mediates the active uptake of Iin the thyroid and other tissues such as salivary glands, gastric mucosa and lactating mammary gland. Physiologically, NIS is expressed in the breast exclusively during gestation and lactation. In vitro and in vivo studies confirmed that lactogenic hormones, including prolactin, can induce functional NIS expression in mammary tissue. Hyperprolactinemia is common in patients with end-stage renal disease (ESRD).","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":"24 2","pages":"122-123"},"PeriodicalIF":0.9,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39303848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Physical quantities useful for quality control of quantitative SPECT/CT imaging. 用于定量SPECT/CT成像质量控制的物理量。
IF 0.9 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2021-01-01 DOI: 10.5603/NMR.2021.0020
Sara Kurkowska, Bożena Birkenfeld, Hanna Piwowarska-Bilska

SPECT/CT imaging is transitioning from solely qualitative applications to quantitative analysis. Quantitative SPECT/CT systems require proper calibration, optimization and quality control. Various types of modern SPECT/CT scanners have different software for calibration and quality control (QC). There is still no standardization in this regard for quantitative SPECT/CT. This issue hinders the exchange of obtained results across centers and stunts the development of repeatable and reproducible measurements. The unification and standardization of calibration and quality control techniques for quantitative SPECT/CT systems is currently a pressing need for nuclear medicine departments. The present study presents three selected physical quantities characterizing the quality of quantitative SPECT/CT system and seven quantities, currently used in the literature, to assess the quality of quantitative SPECT/CT images. The measurement of these parameters requires the use of standard gamma camera software for QC, external programs for quantitative analysis of recorded data and clinical software. The authors hope this will help physicists who are willing to perform quantitative SPECT/CT in their departments.

SPECT/CT成像正在从单纯的定性应用向定量分析过渡。定量SPECT/CT系统需要适当的校准,优化和质量控制。各种类型的现代SPECT/CT扫描仪具有不同的校准和质量控制(QC)软件。定量SPECT/CT在这方面还没有标准化。这个问题阻碍了各中心之间获得的结果的交换,并阻碍了可重复和可再现测量的发展。定量SPECT/CT系统的校准和质量控制技术的统一和标准化是当前核医学部门迫切需要解决的问题。本研究提出了表征定量SPECT/CT系统质量的三个物理量和目前文献中用于评估定量SPECT/CT图像质量的七个物理量。这些参数的测量需要使用标准的伽马相机软件进行QC,外部程序进行记录数据的定量分析和临床软件。作者希望这将有助于物理学家谁愿意执行定量SPECT/CT在他们的部门。
{"title":"Physical quantities useful for quality control of quantitative SPECT/CT imaging.","authors":"Sara Kurkowska,&nbsp;Bożena Birkenfeld,&nbsp;Hanna Piwowarska-Bilska","doi":"10.5603/NMR.2021.0020","DOIUrl":"https://doi.org/10.5603/NMR.2021.0020","url":null,"abstract":"<p><p>SPECT/CT imaging is transitioning from solely qualitative applications to quantitative analysis. Quantitative SPECT/CT systems require proper calibration, optimization and quality control. Various types of modern SPECT/CT scanners have different software for calibration and quality control (QC). There is still no standardization in this regard for quantitative SPECT/CT. This issue hinders the exchange of obtained results across centers and stunts the development of repeatable and reproducible measurements. The unification and standardization of calibration and quality control techniques for quantitative SPECT/CT systems is currently a pressing need for nuclear medicine departments. The present study presents three selected physical quantities characterizing the quality of quantitative SPECT/CT system and seven quantities, currently used in the literature, to assess the quality of quantitative SPECT/CT images. The measurement of these parameters requires the use of standard gamma camera software for QC, external programs for quantitative analysis of recorded data and clinical software. The authors hope this will help physicists who are willing to perform quantitative SPECT/CT in their departments.</p>","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":"24 2","pages":"93-98"},"PeriodicalIF":0.9,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39303512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
NUCLEAR MEDICINE REVIEW
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1